Novartis launches Jakavi in 50+ countries; J&J to market hep C drug in Europe;

> Novartis ($NVS) has launched myelofibrosis drug Jakavi in Singapore and 50 other countries. Report

> Johnson & Johnson's ($JNJ) Janssen has won EU marketing authorization for hep C drug Olysio. Release

> Tolmar Pharma has regained marketing rights for prostate cancer drug Eligard in the U.S. and Puerto Rico. More

> A new report highlights the meningococcal vaccines market through 2019. Release

And Finally... Some tech companies are betting that sifting through patients' social media posts will yield critical side-effect insights that drugmakers will buy. More

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.

The CD19 antibody, used in tandem with Celgene's Revlimid, represents the first FDA approval in second-line diffuse large B-cell lymphoma.